Get the Stockscreener App
1.51
6.21%
-0.10
After Hours:
1.58
0.07
+4.64%
Fractyl Health Inc stock is traded at $1.51, with a volume of 279.06K.
It is down -6.21% in the last 24 hours and down -25.25% over the past month.
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
See More
Previous Close:
$1.61
Open:
$1.63
24h Volume:
279.06K
Relative Volume:
0.79
Market Cap:
$74.98M
Revenue:
-
Net Income/Loss:
$-56.85M
P/E Ratio:
-0.9686
EPS:
-1.559
Net Cash Flow:
-
1W Performance:
-17.93%
1M Performance:
-25.25%
6M Performance:
-22.16%
1Y Performance:
-85.59%
1-Day Range:
$1.51
$1.64
1-Week Range:
$1.51
$1.82
52-Week Range:
$1.51
$10.69
Fractyl Health Inc Stock (GUTS) Company Profile
Name
Fractyl Health Inc
Sector
Industry
Phone
781-902-8800
Address
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
1.51 | 74.98M | 0 | -56.85M | 0 | -1.559 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-24 | Initiated | Evercore ISI | Outperform |
| Feb-27-24 | Initiated | BofA Securities | Buy |
| Feb-27-24 | Initiated | Morgan Stanley | Overweight |
Fractyl Health Inc Stock (GUTS) Latest News
Fractyl Health (NASDAQ:GUTS) Price Target Cut to $10.00 by Analysts at Morgan Stanley - MarketBeat
Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan Sells 90,972 Shares - MarketBeat
Potential Price Increase for Fractyl Health Inc (GUTS) After Recent Insider Activity - Knox Daily
BlackRock, Inc. Increases Stake in Fractyl Health Inc: A Strategic Move in Biotechnology - GuruFocus.com
Fractyl Health, Inc. (NASDAQ:GUTS) Stock Position Lifted by JPMorgan Chase & Co. - Defense World
Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) Insider Sells 22,346 Shares of Stock - MarketBeat
Fractyl Health Inc (GUTS) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Trading Day Triumph: Fractyl Health Inc (GUTS) Ends at 1.70, a -7.61 Surge/Plunge - The Dwinnex
Fractyl Health (NASDAQ:GUTS) Given New $10.00 Price Target at Morgan Stanley - Defense World
Fractyl Health announces layoffs as it pivots to gene therapy - Mass Device
Burlington biotech company announces layoffs, pivots research focus - NBC Boston
Fractyl Health Announces Increased Focus on Groundbreaking - GlobeNewswire
Fractyl Health pivots Type 2 diabetes device therapy toward obesity and GLP-1s, lays off 17% of staff - Fierce Biotech
Fractyl Health announces increased focus on Revita, Rejuva programs - TipRanks
Fractyl Health Reprioritizes Focus on REMAIN-1 Study - TipRanks
Weight Loss Breakthrough: Fractyl's Post-GLP-1 Maintenance Program Shows Promise as Company Pivots Strategy - StockTitan
Burlington biotech slims down 17% of workforce, focuses on weight maintenance treatment - The Business Journals
Barclays PLC Grows Position in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Growth in Short Interest - MarketBeat
Head-To-Head Analysis: Tactile Systems Technology (NASDAQ:TCMD) and Fractyl Health (NASDAQ:GUTS) - Defense World
Fractyl Health’s Promising Progress in Weight Management - TipRanks
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort - The Manila Times
Fractyl Health Announces Positive Initial Clinical Results - GlobeNewswire
Fractyl Health Reports Breakthrough: Patient Maintains 15% Weight Loss After GLP-1 Discontinuation - StockTitan
Geode Capital Management LLC Has $1.27 Million Stock Position in Fractyl Health, Inc. (NASDAQ:GUTS) - MarketBeat
Geode Capital Management LLC Acquires 313,335 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Barclays PLC Has $121,000 Position in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Here’s Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10 - Insider Monkey
State Street Corp Purchases 63,968 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
HighTower Advisors LLC Takes $38,000 Position in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
BNP Paribas Financial Markets Increases Stake in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Charles Schwab Investment Management Inc. Has $204,000 Stock Position in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Critical Contrast: Fractyl Health (GUTS) and Its Rivals - Defense World
GUTSFractyl Health, Inc. Latest Stock News & Market Updates - StockTitan
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRD - GlobeNewswire
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local - The Bakersfield Californian
Fractyl Health's GLP-1 Gene Therapy Shows Breakthrough Results in Preclinical Study5x Higher Expression - StockTitan
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - The Manila Times
Fractyl Health to Present Breakthrough GLP-1 Gene Therapy Data for Diabetes Treatment at WCIRDC 2024 - StockTitan
Is Fractyl Health (NASDAQ:GUTS) Using Debt Sensibly? - Simply Wall St
Analysts Update Their Estimates For Alpha Teknova Inc - Stocks Register
Pulmonx (NASDAQ:LUNG) vs. Fractyl Health (NASDAQ:GUTS) Head-To-Head Review - Defense World
Fractyl Health to Participate in the Upcoming December Conferences - GlobeNewswire
Fractyl Health CEO to Present at Evercore, Piper Sandler Healthcare Conferences - StockTitan
Fractyl Health Stock Price Prediction: 2024, 2025, 2030 - Benzinga
Why This Penny Stock Lost 13% Last Week While Markets Soared - MSN
Comparing Fractyl Health (GUTS) and Its Rivals - Defense World
Comparing Fractyl Health (GUTS) and Its Peers - Defense World
Head to Head Analysis: Fractyl Health (GUTS) versus Its Peers - Defense World
Fractyl Health management to meet virtually with B. Riley - Nasdaq
Lee Ainslie's Strategic Reduction in Fractyl Health Inc Holdings - GuruFocus.com
Fractyl Health Inc Stock (GUTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fractyl Health Inc Stock (GUTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Option Exercise |
1.70 |
20,948 |
35,612 |
512,277 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 31 '25 |
Sale |
1.82 |
90,972 |
165,205 |
491,329 |
| Rajagopalan Harith | Chief Executive Officer |
Jan 30 '25 |
Sale |
1.95 |
20,948 |
40,798 |
491,329 |
| Caplan Jay David | President, Chief Product Off. |
Jan 31 '25 |
Option Exercise |
1.70 |
22,346 |
37,988 |
175,890 |
| Caplan Jay David | President, Chief Product Off. |
Jan 30 '25 |
Option Exercise |
1.70 |
21,472 |
36,502 |
175,016 |
| Caplan Jay David | President, Chief Product Off. |
Jan 30 '25 |
Sale |
1.95 |
21,472 |
41,802 |
153,544 |
| Caplan Jay David | President, Chief Product Off. |
Jan 31 '25 |
Sale |
1.81 |
22,346 |
40,464 |
153,544 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):